Online inquiry

IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1515MR)

This product GTTS-WQ1515MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets INHBA gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002192.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3624
UniProt ID P08476
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1515MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4871MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ7504MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ8962MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ12224MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ3886MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ5376MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ7353MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ7456MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW